“‘GLP Agonists (psych)’ Tag”,2022-01-05 (alcoholism, willpower)⁠:

Bibliography for tag longevity/glp/psychology, most recent first: 1 related tag, 40 annotations, & 7 links (parent).

• See Also
• Links
  • “Ozempic Could Crush the Junk Food Industry. But It Is Fighting Back.”
  • “The Association between Glucose-Dependent Insulinotropic Polypeptide And/or Glucagon-Like Peptide-1 Receptor Agonist Prescriptions and Substance-Related Outcomes in Patients With Opioid and Alcohol Use Disorders: A Real-World Data Analysis”, Qeadan et al 2024
  • “The Association between Glucose-Dependent Insulinotropic Polypeptide And/or Glucagon-Like Peptide-1 Receptor Agonist Prescriptions and Substance-Related Outcomes in Patients With Opioid and Alcohol Use Disorders: A Real-World Data Analysis”, Qeadan et al 2024
  • “Why Do Obesity Drugs Seem to Treat so Many Other Ailments?”
  • “[The Hunger-Noise Monster]”
  • “NYC Law Student Addicted to Cheese Went to Nearly $6K-Per-Week Rehab”, Levine & Sedacca2024
  • “They Promoted Body Positivity. Then They Lost Weight: Do Plus-Size Influencers Owe Their Followers an Explanation When Their Bodies Change?”, Baker2024
  • “Substantial Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series”, Richards et al 2023
  • “Sharon Osbourne Quit Ozempic Because She’s ‘Too Skinny’”, Wickman2023
  • “GWAS of Random Glucose in 476,326 Individuals Provide Insights into Diabetes Pathophysiology, Complications and Treatment Stratification”, Lagou et al 2023
  • “People on Drugs Like Ozempic Say Their ‘Food Noise’ Has Disappeared: For Some, It’s a Startling Side Effect”, Blum2023
  • “Brain Responses to Nutrients Are Severely Impaired and Not Reversed by Weight Loss in Humans With Obesity: a Randomized Crossover Study”, Galen et al 2023
  • “What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know”, Reynolds2023
  • “I Lost 40 Pounds on Ozempic. But I’m Left With Even More Questions.”, Marcus2023
  • “Ozempic’s Next Act: People Taking the Drug for Weight Loss Say They Have Also Stopped Drinking, Smoking, Shopping, and Even Nail-Biting”, Zhang2023
  • “Effects of Liraglutide on Depressive Behavior in a Mouse Depression Model and Cognition in the Probe Trial of Morris Water Maze Test”, Seo et al 2023b
  • “Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study”, Yammine et al 2023
  • “Semaglutide Reduces Alcohol Intake and Relapse-Like Drinking in Male and Female Rats”, Aranäs et al 2023
  • “The Potential Antidepressant Effect of Antidiabetic Agents: New Insights from a Pharmacovigilance Study Based on Data from the Reporting System Databases FAERS and VigiBase”, Battini et al 2023
  • “Protective Role of IGF-1 and GLP-1 Signaling Activation in Neurological Dysfunctions”, Bhalla et al 2022
  • “Dose Titration With the Glucagon-Like Peptide-1 Agonist, Liraglutide, Reduces Cue- and Drug-Induced Heroin Seeking in High Drug-Taking Rats”, Evans et al 2022
  • “Glucagon-Like Peptide 1 Receptor Activation Inhibits Microglial Pyroptosis via Promoting Mitophagy to Alleviate Depression-Like Behaviors in Diabetic Mice”, Yang et al 2022
  • “Treating Cognitive Impairment in Schizophrenia With GLP-1RAs: an Overview of Their Therapeutic Potential”, Flintoff et al 2021
  • “Testing the Effects of the GLP-1 Receptor Agonist Exenatide on Cocaine Self-Administration and Subjective Responses in Humans With Cocaine Use Disorder”, Angarita et al 2021
  • “Activation of GLP-1 Receptors Attenuates Oxycodone Taking and Seeking without Compromising the Antinociceptive Effects of Oxycodone in Rats”, Zhang et al 2020
  • “GABA Neurons in the Nucleus Tractus Solitarius Express GLP-1 Receptors and Mediate Anorectic Effects of Liraglutide in Rats”, Fortin et al 2020
  • “Glucagon-Like Peptide-1 Receptors within the Nucleus of the Solitary Tract Regulate Alcohol-Mediated Behaviors in Rodents”, Vallöf et al 2019
  • “Effects of Glucagon-Like Peptide 1 Analogs on Alcohol Intake in Alcohol-Preferring Vervet Monkeys”, Thomsen et al 2019
  • “Longer-Term Liraglutide Administration at the Highest Dose Approved for Obesity Increases Reward-Related Orbitofrontal Cortex Activation in Response to Food Cues: Implications for Plateauing Weight Loss in Response to Anti-Obesity Therapies”, Farr et al 2019
  • “Glucagon-Like Peptide-1 Receptor Agonists for Antipsychotic-Associated Cardio-Metabolic Risk Factors: A Systematic Review and Individual Participant Data Meta-Analysis”, Siskind et al 2018
  • “Liraglutide for Psychiatric Disorders: Clinical Evidence and Challenges”, Camkurt et al 2018
  • “Cognitive Dysfunction and Metabolic Comorbidities in Mood Disorders: A Repurposing Opportunity for Glucagon-Like Peptide 1 Receptor Agonists?”, Mansur et al 2018
  • “Glucagon-Like Peptide-1 Receptor Activation in the Ventral Tegmental Area Attenuates Cocaine Seeking in Rats”, Hernandez et al 2018
  • “No Cognitive-Enhancing Effect of GLP-1 Receptor Agonism in Antipsychotic-Treated, Obese Patients With Schizophrenia”, Ishøy et al 2017
  • “Central & Peripheral Glucagon-Like Peptide-1 Receptor Signaling Differentially Regulate Addictive Behaviors”, Sirohi et al 2016
  • “Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Prevents Development of Tolerance to Anti-Anxiety Effect of Ethanol and Withdrawal-Induced Anxiety in Rats”, Sharma et al 2014
  • “Neuronal GLP1R Mediates Liraglutide’s Anorectic but Not Glucose-Lowering Effect”, Sisley et al 2014
  • “Liraglutide: Short-Lived Effect on Gastric Emptying—Long Lasting Effects on Body Weight”, Jelsing et al 2012
  • “Drugs Developed to Treat Diabetes, Liraglutide and Lixisenatide, Cross the Blood Brain Barrier and Enhance Neurogenesis”, Hunter & Hölscher2012
  • “Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4”, Kanoski et al 2011
  • Sort By Magic
    • body-image
    • glp1-research
    • addiction-regulation
    • liraglutide-impact
  • Wikipedia
• Miscellaneous
• Bibliography